alexa Bioequivalence Evaluation of Two Brands of Ketoprofen 50 Mg Capsules (Flogofin®andProfenid®) In Healthy Latin American Volunteers

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Recommended Conferences

World Clinical Cancer Research and Diagnosis

Tokyo, Japan

Global Summit on Oncology and Cancer Therapy

New York, USA

Advancement in Drug Discovery

New York, USA
Bioequivalence Evaluation of Two Brands of Ketoprofen 50 Mg Capsules (Flogofin®&Profenid®) In Healthy Latin American Volunteers

The study was performed to compare the bioavailability of two ketoprofen capsule (50 mg) formulations: Flogofin®, as test formulation, and Profenid®, as reference formulation. The study was conducted open with randomized two period crossover design and 1 week washout period in 24 fasting, healthy latino-american male volunteers and performed at the Biopharmaceutical Research Center Dominguez Lab. After dosing, serial blood samples were collected for a period of 24 h and plasma was separated and analyzed for ketoprofen, using a sensitive, reproducible, and accurate method by liquid chromatography – tandem mass spectrometry (LC-MS/MS). Pharmacokinetic parameters: AUC0-24, AUC0-∞, Cmax, Tmax, T1/2 and Ke, were analyzed from plasma concentrations of both formulations. The means AUC0-24 for test and reference formulation were 50.21 ([μg h]/mL) - 50.28 ([μgh]/mL), 52.38 ([μg h]/mL) - 50.84 ([μg h]/mL) for AUC0-∞, and 21.58 μg/mL - 21.65 μg/mL for Cmax, respectively. Statistical modules (ANOVA and 90% confidence intervals) were applied to AUC0–24, AUC0-∞, and Cmax to assess the bioequivalence of the two brands which revealed no significant difference between them, and 90% CI fell within the accepted bioequivalence range of 80%-125%. Based on these statistical inferences, both formulations were found to be bioequivalent.

Citation: Baldo MN, Hunzicker GA, Altamirano JC, Murguía MC, Hein GJ (2015) Bioequivalence Evaluation of Two Brands of Ketoprofen 50 Mg Capsules (Flogofin®&Profenid®) In Healthy Latin American Volunteers. J Bioequiv Availab 7:108-111. doi: 10.4172/jbb.1000223

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
Top